Margarida Maia, PhD,  science writer—

Nearly 8% of people with cystic fibrosis (CF) may be infected with nontuberculous mycobacteria (NTM), a type of bacteria in the environment, a meta-analysis study has found. Researchers observed that the number of cases has surged across the world over the last few years. The bacteria can cause infection…

Trikafta (elexacaftor/tezacaftor/ivacaftor) was seen to keep lung function from getting worse in people with cystic fibrosis (CF) for up to two years, a study found. These findings counter previous studies wherein the active ingredients in Trikafta, alone or in combinations of two, were seen to slow, but not…

Sionna Therapeutics is forging ahead in the new year with its preclinical and clinical programs aimed at developing small molecules — such as SION-638 — as possible treatments for cystic fibrosis (CF). An ongoing Phase 1 trial, now enrolling participants, is testing SION-638 in healthy volunteers. Dosing…

Pseudomonas aeruginosa bacteria can become resistant to the antibiotic tobramycin by clumping into more and larger aggregates and making more of a protective sugar molecule called Psl, a study reported. It used samples of sputum from a small group of children with cystic fibrosis (CF) who received inhaled…

Women with cystic fibrosis (CF) who had a lung transplant are at higher risk of testing positive for the human papillomavirus (HPV), a virus that can cause many cancers, a French study found. Researchers also observed that it was more common for these women than for the general population…

The rate of new cases, or incidence of cystic fibrosis (CF) is gradually and annually decreasing in the U.S. and Canada alike — and has been for nearly a quarter of century — a new study found. From 1995 to 2019, CF incidence has dropped at a rate of…

Most people with cystic fibrosis (CF) have fungi in their airways, but the fungi may come and go in waves of activity, a Spanish study suggests. The study, “Fungal microbiota dynamics and its geographical, age and gender variability in patients with cystic fibrosis,” was published in Clinical Microbiology…

Treatment with Trikafta continues to be safe and well-tolerated, benefiting people with cystic fibrosis (CF) ages 12 and up who have been on treatment for almost three years. But benefits may also extend to children as young as 2. That’s according to data that will be shared at…

A Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, Adaptive Phage’s experimental cocktail of bacteriophages, or viruses that selectively target and kill bacteria, is now recruiting cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa infections. The study (NCT05453578) seeks to enroll up to 72 adults with CF who test positive…

Trikafta (elexacaftor/tezacaftor/ivacaftor) may bring health-related quality of life benefits to people with cystic fibrosis (CF) that go beyond those already reported for breathing, a study found. This expectation stems from a new look by an international team of researchers into data from the two Phase 3 clinical trials that…